• Lexaria’s GLP-1 industry update flagged accelerating demand for oral weight-loss drugs, citing 3 million Wegovy pill prescriptions filled since Jan. 5, 2026.
• The report highlighted market expansion beyond obesity, pointing to late-stage data showing up to 28.3% average weight loss with Lilly’s retatrutide.
• Sales forecasts were raised across the sector, including a TD Cowen 2030 GLP-1 estimate lifted to USD 139 billion from USD 101 billion.
• Safety remained the key product battleground, with gastrointestinal side effects cited as the main barrier to broader uptake.
• Lexaria positioned its DehydraTECH delivery approach as a potential mitigant, citing animal-study results showing 31% to 100% reductions in GI adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202606170925TNWSWRCACNPR_____1AlpF49p9) on June 17, 2026, and is solely responsible for the information contained therein.